Hospitals that serve the more vulnerable population perform worse with their readmission rate following cancer surgery, and the subsequent penalties that they face can further strain the hospital’s already burdened finances.
Hospitals that serve the more vulnerable population perform worse with their readmission rate, and the subsequent penalties that they face can further strain the hospital’s already burdened finances. These are the conclusions from a new study, published online in the Journal of the American College of Surgeons, which evaluated the readmission rate in patients following cancer surgery.
Nearly 110,900 patients who underwent complex surgeries for their cancer—between January 1, 2004, and September 30, 2011, in California—were identified. Vulnerable hospitals were defined as either self-identified safety net hospitals (SNH) or hospitals with high percentage of Medicaid patients (high Medicaid hospitals, HMH). Of the 355 hospitals that were included in the analysis, 13 were SNH and 31 were HMH. After adjusting for Hospital Readmissions Reduction Program (HRRP) variables, the study found that:
Further, with respect to patient demographics, patients who were admitted for surgeries in vulnerable hospitals, compared with non-vulnerable hospitals, were:
Additionally, HMH hospitals saw a significantly greater number of patients of Hispanic origin enrolled.
While multiple factors can influence readmission rates, socioeconomic and hospital characteristics bear significant weight. Penalizing hospitals for high readmission rates without understanding these influences can add significant stress on a hospital’s resources. A report released by Kaiser Health News last year found that following inception of the HRRP, readmission rates dropped overall, but 1 in 5 hospitalized Medicare patients were still readmitted to the hospital within 30 days. These numbers underscore the vulnerable nature of hospitals that serve these patients.
“Different hospitals have different patient mixes, and if that is not factored in, HRRP reductions in payment may further marginalize financially vulnerable hospitals,” said corresponding study author Waddah B. Al-Refaie, MD, FACS, chief of surgical oncology, MedStar Georgetown University Hospital, in a press release.
Reference
Hong Y, Zheng C, Hechenbleikner E, et al. Vulnerable hospitals and cancer surgery readmissions: Insights into the unintended consequences of the Patient Protection and Affordable Care Act [published online May 31, 2016]. J Am Coll Surg. doi:http://dx.doi.org/10.1016/j.jamcollsurg.2016.04.042.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More